Home › Dompé Announces The EMA Has Granted Orphan Drug Designation To Its rhNGF-Based Treatment For Retinitis Pigmentosa
 

Keywords :   


Dompé Announces The EMA Has Granted Orphan Drug Designation To Its rhNGF-Based Treatment For Retinitis Pigmentosa

2013-07-01 09:05:00| drugdiscoveryonline News Articles

Dompé, a leading company in research & development of novel treatment solutions for rare diseases, announces its investigational drug based on the recombinant human nerve growth factor (rhNGF) for the treatment of retinitis pigmentosa (RP) has been granted orphan drug designation

Tags: treatment drug granted announces

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.11 onecontrol Chamaeleo Tail Loop MKII
16.11ZIGGY ORDER-MADE
16.116
16.11SwitchCoLotta
16.11 p8
16.11mtg foil 3
16.11RolandSP-404SX
16.11DVD 42
More »